Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:BNTC NASDAQ:GLUE NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$27.91+1.4%$29.70$22.24▼$46.00$1.65B0.581.02 million shs99,709 shsBNTCBenitec Biopharma$12.54+3.3%$11.73$9.85▼$17.15$431.83M0.28145,636 shs18,531 shsGLUEMonte Rosa Therapeutics$19.53-1.4%$17.69$3.51▼$25.77$1.64B1.621.41 million shs86,881 shsVIRVir Biotechnology$9.33+0.6%$9.61$4.16▼$11.66$1.50B1.73.00 million shs393,559 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.04%-1.68%-21.59%+3.77%-2.27%BNTCBenitec Biopharma-3.42%+0.75%+11.27%+0.17%-10.34%GLUEMonte Rosa Therapeutics-2.84%+3.45%+15.71%+1.33%+414.55%VIRVir Biotechnology-9.91%-9.30%+1.09%+28.93%+65.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$27.91+1.4%$29.70$22.24▼$46.00$1.65B0.581.02 million shs99,709 shsBNTCBenitec Biopharma$12.54+3.3%$11.73$9.85▼$17.15$431.83M0.28145,636 shs18,531 shsGLUEMonte Rosa Therapeutics$19.53-1.4%$17.69$3.51▼$25.77$1.64B1.621.41 million shs86,881 shsVIRVir Biotechnology$9.33+0.6%$9.61$4.16▼$11.66$1.50B1.73.00 million shs393,559 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.04%-1.68%-21.59%+3.77%-2.27%BNTCBenitec Biopharma-3.42%+0.75%+11.27%+0.17%-10.34%GLUEMonte Rosa Therapeutics-2.84%+3.45%+15.71%+1.33%+414.55%VIRVir Biotechnology-9.91%-9.30%+1.09%+28.93%+65.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.5648.89% UpsideBNTCBenitec Biopharma 2.57Moderate Buy$27.67120.63% UpsideGLUEMonte Rosa Therapeutics 2.63Moderate Buy$32.8067.94% UpsideVIRVir Biotechnology 2.89Moderate Buy$20.38118.50% UpsideCurrent Analyst Ratings BreakdownLatest BNTC, GLUE, AGIO, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.004/20/2026BNTCBenitec Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $50.004/10/2026VIRVir Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $36.004/1/2026AGIOAgios Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$28.00 ➝ $32.003/27/2026AGIOAgios Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/18/2026GLUEMonte Rosa Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $29.003/18/2026GLUEMonte Rosa Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $30.003/9/2026BNTCBenitec Biopharma TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M30.72N/AN/A$18.65 per share1.50BNTCBenitec BiopharmaN/AN/AN/AN/A$3.71 per shareN/AGLUEMonte Rosa Therapeutics$123.67M13.33N/AN/A$3.58 per share5.46VIRVir Biotechnology$68.56M21.93N/AN/A$5.50 per share1.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%N/ABNTCBenitec Biopharma-$37.92M-$1.14N/AN/AN/AN/A-38.92%-37.68%5/13/2026 (Estimated)GLUEMonte Rosa Therapeutics-$38.63M-$0.46N/AN/AN/A-31.23%-15.12%-9.30%N/AVIRVir Biotechnology-$437.99M-$3.16N/AN/AN/A-638.88%-49.31%-38.74%N/ALatest BNTC, GLUE, AGIO, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q3 2026BNTCBenitec Biopharma-$0.27N/AN/AN/A$4.55 millionN/A5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3796-$0.45-$0.0704-$0.45$11.41 million$4.21 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/17/2026Q4 2025GLUEMonte Rosa Therapeutics-$0.45-$0.55-$0.10-$0.55$17.09 million$2.78 million2/23/2026Q4 2025VIRVir Biotechnology-$0.42-$0.31+$0.11-$0.31$19.91 million$64.07 million2/12/2026Q2 2026BNTCBenitec Biopharma-$0.23-$0.26-$0.03-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59BNTCBenitec BiopharmaN/A67.6967.69GLUEMonte Rosa TherapeuticsN/A6.126.12VIRVir BiotechnologyN/A5.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ABNTCBenitec Biopharma52.19%GLUEMonte Rosa Therapeutics79.96%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%BNTCBenitec Biopharma4.80%GLUEMonte Rosa Therapeutics6.90%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableBNTCBenitec Biopharma2034.35 million32.71 millionNo DataGLUEMonte Rosa Therapeutics9084.38 million78.56 millionOptionableVIRVir Biotechnology580161.23 million135.44 millionOptionableBNTC, GLUE, AGIO, and VIR HeadlinesRecent News About These CompaniesLocal wins and global moves shape a diverse news week1 hour ago | msn.comVir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 20281 hour ago | msn.comVir Biotechnology, Inc. Q1 2026 Earnings Call Summary1 hour ago | finance.yahoo.comVir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call TranscriptMay 7 at 6:11 AM | seekingalpha.comVir Biotechnology Q1 Earnings Call HighlightsMay 7 at 4:17 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Posts Earnings ResultsMay 6 at 4:26 PM | marketbeat.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 6 at 4:05 PM | businesswire.comVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare ConferenceMay 5 at 4:05 PM | businesswire.comVir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of StockMay 5 at 4:57 AM | americanbankingnews.comVicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) StockMay 5 at 4:52 AM | insidertrades.comVir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 SharesMay 4, 2026 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 3, 2026 | marketbeat.comWhy Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii ArbitrationApril 29, 2026 | finance.yahoo.comVir Biotechnology (VIR) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?April 27, 2026 | finance.yahoo.comVir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsApril 23, 2026 | businesswire.comVir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study UpdateApril 23, 2026 | tipranks.com10 Best Small-Cap Biotech Stocks According to Hedge FundsApril 21, 2026 | insidermonkey.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - Here's WhyApril 20, 2026 | marketbeat.comCan Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?April 20, 2026 | insidermonkey.comIs Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?April 19, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNTC, GLUE, AGIO, and VIR Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$27.91 +0.38 (+1.38%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Benitec Biopharma NASDAQ:BNTC$12.54 +0.40 (+3.29%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Monte Rosa Therapeutics NASDAQ:GLUE$19.53 -0.28 (-1.41%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Vir Biotechnology NASDAQ:VIR$9.32 +0.06 (+0.59%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
